Being a very common condition among the whole population of the world, often leading a life-threatening illness and having high risk and mortality rate, chronic heart failure is also a major public health problem for the world. According to data provided in 2017, 26 million people worldwide suffer from heart failure. These reasons include especially malnutrition and obesity, diabetes mellitus that is increasing every year, increase in smoking, hypertension, and an increase of alcohol consumption. Our goal is to investigate what has been achieved in the treatment of chronic heart failure patients with a Left Ventricular Ejection Fraction (LVEF) < 40% recent years. In recent years, it is revealed that brain natriuretic peptide has been crucial in the pathogenesis of heart disease. The activity of natriuretic peptides, in particular B-type natriuretic peptide, causes a number of significant cardiac and renal effects. Thus, B-type natriuretic peptide has a significant role in the diagnosis of heart failure and in the evaluation of its prognosis. However, natriuretic peptides can not last long in the body and break down quickly. This process is mainly due to neprilysin and that is why, neprilysin inhibition is needed in order to prevent the process. Due to this reason, we tried to investigate the results of the complex medical treatment method performed with the combination of sacubitril / valsartan which is neprilysin inhibitor in chronic heart failure patients. We also investigated the device treatment methods used in the treatment of these patients, particularly the cardiac resynchronization therapy.
Finally, we investigated the results of the complex medical treatment method performed with the combination of sacubitril / valsartan in comparison with the results of the device treatment methods.